Label
Interaction expected – Do not coadminister
Color
Red
Red: Avoid combination
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Dolutegravir Aluminum and magnesium hydroxide antacid 122 | Red: Avoid combination | Do not coadminister: Reduced levels of dolutegravir | Potential decrease in antiretroviral efficacy |
Cmax decreased 72%, AUC decreased 74%, Cmin decreased 74% |
Maalox given simultaneously as dolutegravir | Not studied |
Administer dolutegravir 2 hours before or 6 hours after antacids. |
| Dolutegravir NVP 121 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of dolutegravir | Potential decrease in antiretroviral efficacy |
Not studied |
Not studied |
Contraindicated. Use alternative agents. |
|
| Dolutegravir St. John's Wort (Hypericum perforatum) 120 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of dolutegravir | Potential decrease in antiretroviral efficacy |
Not studied (may decreased dolutegravir levels) |
Not studied |
Contraindicated. Use alternative agents. |
|
| Dolutegravir RPT 119 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of dolutegravir | Potential decrease in antiretroviral efficacy |
Not studied (may decreased dolutegravir levels) |
Not studied |
Contraindicated. Use alternative agents. |
|
| Dolutegravir Phenytoin 118 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of dolutegravir | Potential decrease in antiretroviral efficacy |
Not studied (may decreased dolutegravir levels) |
Not studied |
Avoid combination or use alternative agents |
|
| Dolutegravir Phenobarbital 117 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of dolutegravir | Potential decrease in antiretroviral efficacy |
Not studied (may decreased dolutegravir levels) |
Not studied |
Avoid combination or use alternative agents |
|
| Dolutegravir Oxcarbazepine 116 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of dolutegravir | Potential decrease in antiretroviral efficacy |
Not studied (may decreased dolutegravir levels) |
Not studied |
Avoid combination or use alternative agents |
|
| Dolutegravir Dofetilide 115 | Red: Avoid combination | Do not coadminister: Potential for increased levels of dofetilide | Potential for increased dofetilide toxicity |
Not studied |
Not studied |
Contraindicated. Use alternative agents. |
|
| Dolutegravir Dalfampridine 114 | Red: Avoid combination | Do not coadminister: Potential for increased levels of dalfampridine | Potential for increased dalfampridine toxicity |
Not studied |
Not studied |
Contraindicated. Use alternative agents. |
|
| Dolutegravir INH 113 | Red: Avoid combination | Do not coadminister: Increased levels of izoniazid and reduced levels of dolutegravir | Potential for increased adverse effects of isoniazid (flu-like symptoms, nausea, vomiting, and fever) |
AUC decreased 46%, Cmin decreased 74% |
15 mg / kg + rifapentine 900 mg once weekly | INH AUC increased 67-92% in 2 / 4 subjects. Rifapentine no significant change. |
Use alternative agents |
| Bictegravir RFB 82 | Red: Avoid combination | Do not coadminister: Reduced levels of bictegravir | Potential decrease in antiretroviral efficacy |
Cmax decreased 20%, AUC decreased 38%, Cmin decreased 56% |
300 mg once daily (fasted) | Not reported |
Use alternative agents |
| Bictegravir RIF 81 | Red: Avoid combination | Do not coadminister: Reduced levels of bictegravir | Potential decrease in antiretroviral efficacy |
Cmax decreased 28%, AUC decreased 75% |
600 mg once daily (fed state) | Not reported |
Contraindicated. Use alternative agents. |
| Bictegravir Phenytoin 80 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of BIC and TAF | Potential decrease in antiretroviral efficacy |
Use alternative agents |
|||
| Bictegravir Phenobarbital 79 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of BIC and TAF | Potential decrease in antiretroviral efficacy |
Use alternative agents |
|||
| Bictegravir Oxcarbazepine 78 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of BIC and TAF | Potential decrease in antiretroviral efficacy |
Use alternative agents |
|||
| Bictegravir CBZ 77 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of BIC and TAF | Potential decrease in antiretroviral efficacy |
Use alternative agents |
|||
| Bictegravir St. John's Wort (Hypericum perforatum) 76 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of BIC and TAF | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Bictegravir Eslicarbazepine 75 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of BIC and TAF | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Bictegravir RPT 74 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of BIC | Potential decrease in antiretroviral efficacy |
Not studied |
Not studied |
Use alternative agents |
|
| Bictegravir Primidone 73 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of BIC | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Bictegravir Enzalutamide 72 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of BIC | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Bictegravir Dofetilide 71 | Red: Avoid combination | Do not coadminister: Potential for increased levels of dofetilide | Potentially increased dofetilide exposure and cardiac arrhythmias |
Contraindicated. Use alternative agents. |
|||
| Maraviroc St. John's Wort (Hypericum perforatum) 60 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of maraviroc | Potential decrease in antiretroviral efficacy |
Use alternative agents |
|||
| Maraviroc Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 59 | Red: Avoid combination | Do not coadminister: Potential for increased levels of maraviroc | Potential maraviroc-associated adverse effects |
Use alternative agents |
|||
| Fostemsavir RIF 24 | Red: Avoid combination | Do not coadminister: Reduced levels of temsavir | Potential decrease in antiretroviral efficacy |
Temsavir Cmax decreased 76%, AUC decreased 82% |
600 mg once daily | Not reported |
Contraindicated. Use alternative agents. |
| Fostemsavir RPT 23 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of temsavir | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Fostemsavir St. John's Wort (Hypericum perforatum) 22 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of temsavir | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Fostemsavir Phenytoin 21 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of temsavir | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Fostemsavir Phenobarbital 20 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of temsavir | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Fostemsavir Mitotane 19 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of temsavir | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Fostemsavir Enzalutamide 18 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of temsavir | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Fostemsavir CBZ 17 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of temsavir | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
